secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0000950170-24-058187
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum signs $80M upfront Sanofi deal for losmapimod ex-U.S.; Q1 net loss $26.9M
--------------------------------------------------------------------------------

- Sanofi pays $80M upfront; Fulcrum eligible for up to $975M in milestones and tiered low-teens to mid-twenties royalties on ex-U.S. sales.
- Cash, equivalents, and securities $213.3M at March 31; pro forma ~$293.3M including Sanofi upfront; runway into 2027.
- Net loss $26.9M for Q1 2024 vs $24.8M in Q1 2023; R&D expenses $19.8M due to REACH trial advancement.
- Phase 3 REACH trial for losmapimod in FSHD on track to report topline data in Q4 2024.
- Appointed Patrick Horn, M.D., Ph.D., as CMO; Phase 1b pociredir trial in sickle cell disease expanding to cohorts 3 and 4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000095017024058187/0000950170-24-058187-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000095017024058187/fulc-20240511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-058187

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer